Cargando…
Development of Sesamol Carbamate-L-Phenylalanine Prodrug Targeting L-Type Amino Acid Transporter1 (LAT1) as a Potential Antiproliferative Agent against Melanoma
Sesamol is a compound reported to have anti-melanogenesis and anti-melanoma actions. Sesamol, however, has low intracellular drug concentration and fast excretion, which can limit its benefits in the clinic. To overcome this drawback and increase intracellular delivery of sesamol into the target mel...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369069/ https://www.ncbi.nlm.nih.gov/pubmed/35955600 http://dx.doi.org/10.3390/ijms23158446 |
_version_ | 1784766344978235392 |
---|---|
author | Srisongkram, Tarapong Bahrami, Katayun Järvinen, Juulia Timonen, Juri Rautio, Jarkko Weerapreeyakul, Natthida |
author_facet | Srisongkram, Tarapong Bahrami, Katayun Järvinen, Juulia Timonen, Juri Rautio, Jarkko Weerapreeyakul, Natthida |
author_sort | Srisongkram, Tarapong |
collection | PubMed |
description | Sesamol is a compound reported to have anti-melanogenesis and anti-melanoma actions. Sesamol, however, has low intracellular drug concentration and fast excretion, which can limit its benefits in the clinic. To overcome this drawback and increase intracellular delivery of sesamol into the target melanoma, research has focused on L-type amino acid transporter 1 (LAT1)-mediated prodrug delivery into melanoma cells. The sesamol prodrug was designed by conjugating sesamol with L-phenylalanine at the para position with a carbamate bond. LAT1 targeting was evaluated vis-à-vis a competitive [(14)C]-leucine uptake inhibition. The sesamol prodrug has a higher [(14)C]-leucine uptake inhibition than sesamol in human LAT1-transfected HEK293 cells. Moreover, the sesamol prodrug was taken up by LAT1-mediated transport into SK-MEL-2 cells more effectively than sesamol. The sesamol prodrug underwent complete hydrolysis, releasing the active sesamol at 72 h, which significantly exerted its cytotoxicity (IC(50) of 29.3 µM) against SK-MEL-cells more than sesamol alone. Taken together, the strategy for LAT1-mediated prodrug delivery has utility for the selective uptake of sesamol, thereby increasing its intracellular concentration and antiproliferation activity, targeting melanoma SK-MEL-2 cells that overexpress the LAT1 protein. The sesamol prodrug thus warrants further evaluation in an in vivo model. |
format | Online Article Text |
id | pubmed-9369069 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93690692022-08-12 Development of Sesamol Carbamate-L-Phenylalanine Prodrug Targeting L-Type Amino Acid Transporter1 (LAT1) as a Potential Antiproliferative Agent against Melanoma Srisongkram, Tarapong Bahrami, Katayun Järvinen, Juulia Timonen, Juri Rautio, Jarkko Weerapreeyakul, Natthida Int J Mol Sci Article Sesamol is a compound reported to have anti-melanogenesis and anti-melanoma actions. Sesamol, however, has low intracellular drug concentration and fast excretion, which can limit its benefits in the clinic. To overcome this drawback and increase intracellular delivery of sesamol into the target melanoma, research has focused on L-type amino acid transporter 1 (LAT1)-mediated prodrug delivery into melanoma cells. The sesamol prodrug was designed by conjugating sesamol with L-phenylalanine at the para position with a carbamate bond. LAT1 targeting was evaluated vis-à-vis a competitive [(14)C]-leucine uptake inhibition. The sesamol prodrug has a higher [(14)C]-leucine uptake inhibition than sesamol in human LAT1-transfected HEK293 cells. Moreover, the sesamol prodrug was taken up by LAT1-mediated transport into SK-MEL-2 cells more effectively than sesamol. The sesamol prodrug underwent complete hydrolysis, releasing the active sesamol at 72 h, which significantly exerted its cytotoxicity (IC(50) of 29.3 µM) against SK-MEL-cells more than sesamol alone. Taken together, the strategy for LAT1-mediated prodrug delivery has utility for the selective uptake of sesamol, thereby increasing its intracellular concentration and antiproliferation activity, targeting melanoma SK-MEL-2 cells that overexpress the LAT1 protein. The sesamol prodrug thus warrants further evaluation in an in vivo model. MDPI 2022-07-30 /pmc/articles/PMC9369069/ /pubmed/35955600 http://dx.doi.org/10.3390/ijms23158446 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Srisongkram, Tarapong Bahrami, Katayun Järvinen, Juulia Timonen, Juri Rautio, Jarkko Weerapreeyakul, Natthida Development of Sesamol Carbamate-L-Phenylalanine Prodrug Targeting L-Type Amino Acid Transporter1 (LAT1) as a Potential Antiproliferative Agent against Melanoma |
title | Development of Sesamol Carbamate-L-Phenylalanine Prodrug Targeting L-Type Amino Acid Transporter1 (LAT1) as a Potential Antiproliferative Agent against Melanoma |
title_full | Development of Sesamol Carbamate-L-Phenylalanine Prodrug Targeting L-Type Amino Acid Transporter1 (LAT1) as a Potential Antiproliferative Agent against Melanoma |
title_fullStr | Development of Sesamol Carbamate-L-Phenylalanine Prodrug Targeting L-Type Amino Acid Transporter1 (LAT1) as a Potential Antiproliferative Agent against Melanoma |
title_full_unstemmed | Development of Sesamol Carbamate-L-Phenylalanine Prodrug Targeting L-Type Amino Acid Transporter1 (LAT1) as a Potential Antiproliferative Agent against Melanoma |
title_short | Development of Sesamol Carbamate-L-Phenylalanine Prodrug Targeting L-Type Amino Acid Transporter1 (LAT1) as a Potential Antiproliferative Agent against Melanoma |
title_sort | development of sesamol carbamate-l-phenylalanine prodrug targeting l-type amino acid transporter1 (lat1) as a potential antiproliferative agent against melanoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369069/ https://www.ncbi.nlm.nih.gov/pubmed/35955600 http://dx.doi.org/10.3390/ijms23158446 |
work_keys_str_mv | AT srisongkramtarapong developmentofsesamolcarbamatelphenylalanineprodrugtargetingltypeaminoacidtransporter1lat1asapotentialantiproliferativeagentagainstmelanoma AT bahramikatayun developmentofsesamolcarbamatelphenylalanineprodrugtargetingltypeaminoacidtransporter1lat1asapotentialantiproliferativeagentagainstmelanoma AT jarvinenjuulia developmentofsesamolcarbamatelphenylalanineprodrugtargetingltypeaminoacidtransporter1lat1asapotentialantiproliferativeagentagainstmelanoma AT timonenjuri developmentofsesamolcarbamatelphenylalanineprodrugtargetingltypeaminoacidtransporter1lat1asapotentialantiproliferativeagentagainstmelanoma AT rautiojarkko developmentofsesamolcarbamatelphenylalanineprodrugtargetingltypeaminoacidtransporter1lat1asapotentialantiproliferativeagentagainstmelanoma AT weerapreeyakulnatthida developmentofsesamolcarbamatelphenylalanineprodrugtargetingltypeaminoacidtransporter1lat1asapotentialantiproliferativeagentagainstmelanoma |